Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05263921 · ClinicalTrials.gov registry record · Phase 1
Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants
A Phase 1 study of Bioavailability, sponsored by Pfizer.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT05263921 is a Phase 1 study of Bioavailability that has completed, run by Pfizer. The registered enrollment target is 12 participants, below the 37-participant average among 8 other Bioavailability trials with a reported enrollment target (68% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05263921, a Phase 1 study of Bioavailability, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to estimate the relative bioavailability of PF-07321332/ritonavir oral powder relative to the commercial tablet formulation under fasted condition in healthy adult participants. The study will also assess the effect of 3 different food vehicles on the relative bioavailability of the PF-07321332/ritonavir oral powder formulation as well as the safety, tolerability, and palatability of PF-07321332/ritonavir oral powder in healthy adult participants.
Conditions Studied
Interventions
- DRUG PF-07321332/ritonavir
Study Locations (1)
Connecticut
- Pfizer Clinical Research Unit - New Haven - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2022-03-10 |
| Est. Completion | 2022-05-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05263921
The ClinicalTrials.gov registry entry for NCT05263921 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 37-participant average among 8 other Bioavailability trials with a reported enrollment target (68% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bioavailability appearing as the primary indexed condition, and to 1 intervention - of which PF-07321332/ritonavir is the first listed.
NCT05263921 reports 1 study location spanning 1 distinct geographic area - top geographies include Connecticut.
Frequently Asked Questions
What is clinical trial NCT05263921 about?
NCT05263921 is a clinical study titled "Relative Bioavailability Study of PF-07321332/Ritonavir Oral Powder Relative to the Commercial Tablets in Healthy Participants". The purpose of this study is to estimate the relative bioavailability of PF-07321332/ritonavir oral powder relative to the commercial tablet formulation under fasted condition in healthy adult participants. The study will also assess the effect of 3 different food vehicles on the relative bioavailab...
What is the current status of trial NCT05263921?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2022-03-10. Estimated completion is 2022-05-19.
What conditions does trial NCT05263921 study?
This clinical trial studies the following conditions: Bioavailability.
What interventions are being tested in trial NCT05263921?
The interventions under investigation include: PF-07321332/ritonavir (DRUG).
Who is sponsoring clinical trial NCT05263921?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05263921 being conducted?
This trial has 1 study location across Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bioavailability
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Curcumin and Retinal Study
RECRUITING · Phase 1
-
A Study of TEPEZZA Subcutaneous Administration in Healthy Adults
COMPLETED · Phase 1
-
A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects
COMPLETED · Phase 1
-
Pharmacokinetics Study of Oral Rivaroxaban in Healthy Participants
COMPLETED · Phase 1
-
Relative Bioavailability Study of 4 Different Formulations of PF-07321332 Relative to the Commercial Tablet Formulation
COMPLETED · Phase 1
-
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Ascending Doses of Intravenous WCK 771
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.